Prognostic value of the immunohistochemistry markers CD56, TTF‑1, synaptophysin, CEA, EMA and NSE in surgically resected lung carcinoid tumors

Georgakopoulou,Vasiliki Epameinondas; Zygouris,Eleftherios; Damaskos,Christos; Pierrakou,Aikaterini; Papalexis,Petros; Garmpis,Nikolaos; Aravantinou‑Fatorou,Aikaterini; Chlapoutakis,Serafeim; Diamantis,Evangelos; Nikokiris,Christos; Gkoufa,Aikaterini; Sklapani,Pagona; Trakas,Nikolaos; Janinis,Jim; Spandidos,Demetrios A.; Dahabreh,Jubrail

doi:10.3892/mco.2021.2464

Prognostic value of the immunohistochemistry markers CD56, TTF‑1, synaptophysin, CEA, EMA and NSE in surgically resected lung carcinoid tumors

Authors:
- Vasiliki Epameinondas Georgakopoulou
- Eleftherios Zygouris
- Christos Damaskos
- Aikaterini Pierrakou
- Petros Papalexis
- Nikolaos Garmpis
- Aikaterini Aravantinou‑Fatorou
- Serafeim Chlapoutakis
- Evangelos Diamantis
- Christos Nikokiris
- Aikaterini Gkoufa
- Pagona Sklapani
- Nikolaos Trakas
- Jim Janinis
- Demetrios A. Spandidos
- Jubrail Dahabreh
View Affiliations

Affiliations: Pulmonology Department, Laiko General Hospital, Athens 11527, Greece, Oncology Department, Athens Medical Group, Athens 15125, Greece, Renal Transplantation Unit, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece, Department of Pathology, Athens Medical Group, Athens 15125, Greece, First Department of Propedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece, N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece, First Department of Internal Medicine, Laiko General Hospital, Athens 11527, Greece, Department of Thoracic Surgery, Agios Savvas Hospital, Athens 11522, Greece, Unit of Endocrinology and Diabetes Center, Athens Hospital G. Gennimatas, Athens 11527, Greece, Intensive Care Unit, Sismanogleio Hospital, Athens 15126, Greece, Department of Cytology, Mitera Hospital, Athens 15123, Greece, Department of Biochemistry, Sismanogleio Hospital, Athens 15126, Greece, Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece
Published online on: December 14, 2021 https://doi.org/10.3892/mco.2021.2464
Article Number: 31
Copyright: © Georgakopoulou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung carcinoid tumor is a type of neuroendocrine tumor, which is subdivided into typical carcinoid (TC) and atypical carcinoid (AT), based on the rate of mitosis and the presence of necrosis. Several prognostic factors for lung carcinoids have been reported in the literature, including the type, Ki67 index, stage, chemotherapy and radiation therapy. In the present study, 108 cases with resected carcinoid lung tumors were enrolled and the expression of CD56, thyroid transcription factor 1, synaptophysin, carcinoembryonic antigen, epithelial membrane antigen and neuron‑specific enolase (NSE) in the resected tissue specimens was immunohistochemically analyzed. Patients with positive staining for NSE had an unfavorable survival prognosis compared with patients with negative staining for NSE (137.2 vs. 150.0 months, P=0.044). According to univariate analysis, none of the above immunohistochemistry markers was associated with survival, and according to multivariate analysis, NSE was an independent influencing factor for survival inpatients with AT (P=0.046) and furthermore, the stage was an independent factor of survival in patients with TC (P=0.005).

View Figures

View References

1	Gosain R, Mukherjee S, Yendamuri SS and Iyer R: Management of typical and atypical pulmonary carcinoids based on different established guidelines. Cancers (Basel). 10(510)2018.PubMed/NCBI View Article : Google Scholar
2	Rosado de Christenson ML, Abbott GF, Kirejczyk WM, Galvin JR and Travis WD: Thoracic carcinoids: Radiologic-pathologic correlation. Radiographics. 19:707–736. 1999.PubMed/NCBI View Article : Google Scholar
3	Hemminki K and Li X: Incidence trends and risk factors of carcinoid tumors: A nationwide epidemiologic study from Sweden. Cancer. 92:2204–2210. 2001.PubMed/NCBI View Article : Google Scholar
4	Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML and Taal BG: Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol. 12:1295–1300. 2001.PubMed/NCBI View Article : Google Scholar
5	Rekhtman N: Neuroendocrine tumors of the lung: An update. Arch Pathol Lab Med. 134:1628–1638. 2010.PubMed/NCBI View Article : Google Scholar
6	Zeng Y, Zhu Y, Ding Y, Xu L, Zhai B, Zhang X, Ge Q, Li J, Song Q, Li X and Zhang Z: Analysis of lung biopsies using the 2015 WHO criteria and detection of sensitizing mutations-a single-institution experience of 5032 cases. Diagn Pathol. 15(59)2020.PubMed/NCBI View Article : Google Scholar
7	Mjønes P, Sagatun L, Nordrum IS and Waldum HL: Neuron-specific enolase as an immunohistochemical marker is better than its reputation. J Histochem Cytochem. 65:687–703. 2017.PubMed/NCBI View Article : Google Scholar
8	Gledhill A, Sparham C and Dixon MF: Expression of epithelial membrane antigen by carcinoid tumours. J Clin Pathol. 43:696–697. 1990.PubMed/NCBI View Article : Google Scholar
9	Bishopric GA Jr and Ordóñez NG: Carcinoembryonic antigen in primary carcinoid tumors of the lung. Cancer. 58:1316–1320. 1986.PubMed/NCBI View Article : Google Scholar
10	Huang Y, Yang X, Lu T, Li M, Zhao M, Yang X, Ma K, Wang S, Zhan C, Liu Y and Wang Q: Assessment of the prognostic factors in patients with pulmonary carcinoid tumor: A population-based study. Cancer Med. 7:2434–2441. 2018.PubMed/NCBI View Article : Google Scholar
11	Georgakopoulou VE, Zygouris E, Nikokiris C, Damaskos C, Pierrakou A, Garmpis N, Garmpi A, Sklapani P, Aravantinou A, Trakas N, et al: Predictive indicators of survival in patients with surgically resected lung carcinoid tumors at a Greek medical center. Cureus. 12(e10300)2020.PubMed/NCBI View Article : Google Scholar
12	Graziano SL, Tatum AH, Newman NB, Oler A, Kohman LJ, Veit LJ, Gamble GP, Coleman MJ, Barmada S and O'Lear S: The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer. Cancer Res. 54:2908–2913. 1994.PubMed/NCBI
13	Yaman B, Nart D, Ekren PK, Çok G and Veral A: Expression of p63, TTF-1 and maspin in non-small cell lung carcinoma and their effect on the prognosis and differential diagnosis. Turk Patoloji Derg. 31:163–174. 2015.PubMed/NCBI View Article : Google Scholar
14	Ather MH, Abbas F, Faruqui N, Israr M and Pervez S: Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol. 8(21)2008.PubMed/NCBI View Article : Google Scholar
15	Tudoraşcu DR, Pirici D, Târtea EA, Mustafa ER, Florescu C, Vere CC, Balea AM, Puiu I, Târtea GC and Albu VC: Synaptophysin expression as prognostic factor for survival in colorectal carcinomas. Rom J Morphol Embryol. 58:1409–1415. 2017.PubMed/NCBI
16	Wang L, Wang Z, Xia ZJ, Lu Y, Huang HQ and Zhang YJ: CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis. Tumour Biol. 36:7717–7723. 2015.PubMed/NCBI View Article : Google Scholar
17	Bamias A, Chorti M, Deliveliotis C, Trakas N, Skolarikos A, Protogerou B, Legaki S, Tsakalou G, Tamvakis N and Dimopoulos MA: Prognostic significance of CA 125, CD44, and epithelial membrane antigen in renal cell carcinoma. Urology. 62:368–373. 2003.PubMed/NCBI View Article : Google Scholar
18	Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, et al: The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 10:1243–1260. 2015.PubMed/NCBI View Article : Google Scholar
19	Feng SH and Yang ST: The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations. Diagn Interv Radiol. 25:270–279. 2019.PubMed/NCBI View Article : Google Scholar
20	Vesterinen T, Mononen S, Salmenkivi K, Mustonen H, Räsänen J, Salo JA, Ilonen I, Knuuttila A, Haglund C and Arola J: Clinicopathological indicators of survival among patients with pulmonary carcinoid tumor. Acta Oncol. 57:1109–1116. 2018.PubMed/NCBI View Article : Google Scholar
21	Ramirez RA, Beyer DT, Diebold AE, Voros BA, Chester MM, Wang YZ, Boudreaux JP, Woltering EA, Uhlhorn AP, Ryan P, et al: Prognostic factors in typical and atypical pulmonary carcinoids. Ochsner J. 17:335–340. 2017.PubMed/NCBI
22	Filosso PL, Ruffini E, Di Gangi S, Guerrera F, Bora G, Ciccone G, Galassi C, Solidoro P, Lyberis P, Oliaro A and Sandri A: Prognostic factors in neuroendocrine tumours of the lung: A single-centre experience. Eur J Cardiothorac Surg. 45:521–526. 2014.PubMed/NCBI View Article : Google Scholar
23	Wang J, Ma Y, Zhu ZH, Situ DR, Hu Y and Rong TH: Expression and prognostic relevance of tumor carcinoembryonic antigen in stage IB non-small cell lung cancer. J Thorac Dis. 4:490–496. 2012.PubMed/NCBI View Article : Google Scholar
24	Ianniello A, Sansovini M, Severi S, Nicolini S, Grana CM, Massri K, Bongiovanni A, Antonuzzo L, Di Iorio V, Sarnelli A, et al: Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: Prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. Eur J Nucl Med Mol Imaging. 43:1040–1046. 2016.PubMed/NCBI View Article : Google Scholar
25	Wang X, Zhang Y, Hu M, Wang R, Liu L, Qian K, Li Y and Zhi X: Prognostic and predictive value of thyroid transcription factor-1, CD56, P40 and other clinical characteristics in small cell lung cancer patients. Zhongguo Fei Ai Za Zhi. 20:522–527. 2017.PubMed/NCBI View Article : Google Scholar : (In Chinese).
26	Feng J, Sheng H, Zhu C, Qian X, Wan D, Su D, Chen X and Zhu L: Correlation of neuroendocrine features with prognosis of non-small cell lung cancer. Oncotarget. 7:71727–71736. 2016.PubMed/NCBI View Article : Google Scholar
27	Touhami H, Sotto JJ, Sotto MF, Couderc P, Keddari E, Brahimi S and Kubisz P: Prognostic value of the epithelial membrane antigen (EMA) in the case of Hodgkin's disease. Neoplasma. 38:433–437. 1991.PubMed/NCBI
28	Kim GJ, Rhee H, Yoo JE, Ko JE, Lee JS, Kim H, Choi JS and Park YN: Increased expression of CCN2, epithelial membrane antigen, and fibroblast activation protein in hepatocellular carcinoma with fibrous stroma showing aggressive behavior. PLoS One. 9(e105094)2014.PubMed/NCBI View Article : Google Scholar
29	Jørgensen LG, Osterlind K, Genollá J, Gomm SA, Hernández JR, Johnson PW, Løber J, Splinter TA and Szturmowicz M: Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): A combined multivariable analysis on data from nine centres. Br J Cancer. 74:463–467. 1996.PubMed/NCBI View Article : Google Scholar
30	Barlési F, Gimenez C, Torre JP, Doddoli C, Mancini J, Greillier L, Roux F and Kleisbauer JP: Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med. 98:357–362. 2004.PubMed/NCBI View Article : Google Scholar
31	Jiang R, Wang X and Li K: Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer. Oncotarget. 7:26823–26836. 2016.PubMed/NCBI View Article : Google Scholar
32	Petrovic M, Tomic I, Plavec G, Ilic S, Ilic N and Baskic D: Neuron specific enolase tissue expression as a prognostic factor in advanced non small cell lung cancer. J BUON. 13:93–96. 2008.PubMed/NCBI
33	Tiseo M, Ardizzoni A, Cafferata MA, Loprevite M, Chiaramondia M, Filiberti R, Marroni P, Grossi F and Paganuzzi M: Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer. Anticancer Res. 28:507–513. 2008.PubMed/NCBI